News

Immunoprecise Opens U.S. Headquarters in Fargo, North Dakota

Victoria, British Columbia, Canada, May 18, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the opening of its U.S. Headquarters in Fargo, North Dakota. The Fargo-Moorhead (FM) region has a strong and diverse economy with a broad base of entrepreneurs who invest in the regions’ companies.  FM and … Continue reading

IMMUNOPRECISE OPENS NEW FULL SERVICE B-CELL FACILITY

Victoria, British Columbia, Canada, April 27, 2018 - IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the opening of its new, innovative full service B-cell facility offering B-cell screening, sorting and sequencing on a broad range of therapeutically-relevant protein families including GPCRs and other multi-membrane spanning proteins.  The immediate benefits to ImmunoPrecise is that … Continue reading

Immunoprecise Announces Oversubscription To Debenture Financing

Victoria, British Columbia, Canada, April 6, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces it has completed a final tranche to its debenture (the “Debentures”) financing in the principal amount of $250,000.  In total, ImmunoPrecise issued $4,252,000 of Debentures under the entire financing. The Debentures are unsecured, bear interest at a … Continue reading

IMMUNOPRECISE ACQUIRES MODIQUEST RESEARCH BV

Immediately Accretive by Adding EBITDA of Approximately C$750,000 with Increased Synergies, Scale and Efficiency Strategic Acquisition Allows ImmunoPrecise to Provide Comprehensive and Next Generation Antibody Therapeutic Discovery Victoria, British Columbia, Canada, April 6, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) is pleased to announce that it has acquired … Continue reading

Immunoprecies Antibodies Delivers Record Quarterly Revenue of $1.723 Million and Increases Gross Margins To 54%

March 28, 2018 – Victoria, British Columbia.  IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX Venture: IPA, OTC PINK: IPATF) today reports its financial results for the third quarter ended January 31, 2018.  The financial statements and related management’s discussion and analysis (“MD&A”) can be viewed on SEDAR at www.sedar.com. During the three months ended … Continue reading

Immunoprecise enters into Definitive Agreement to Acquire ModiQuest Research BV

Victoria, British Columbia, Canada, March 16, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “Immunoprecise”) (TSX VENTURE: IPA)(OTC PINK: IPATF) is pleased to announce that it has entered into the definitive share purchase agreement (the “Definitive Agreement”) to acquire all of the issued and outstanding shares of ModiQuest Research B.V. (“ModiQuest“) and Immulease B.V. (“Immulease”). … Continue reading

Immunoprecise to Strategically Invest in Foundational Next Generation Antibody Discovery Technology

Victoria, British Columbia, Canada, January 22, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a letter of intent with Single Cell Technology, Inc. (“Single Cell”) whereby the Company has agreed to strategically invest $5M (USD) in the expansion and development of production capability for Single Cell’s … Continue reading

ImmunoPrecise to Acquire Crossbeta Research BV

Victoria, British Columbia, Canada, December 22, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with Crossbeta Biosciences B.V. (“Crossbeta“) whereby the Company has agreed to acquire all of the issued and outstanding shares of Crossbeta (the “Transaction”). The Transaction continues to … Continue reading

ImmunoPrecise to Acquire ModiQuest Research BV

VICTORIA, Dec. 7, 2017 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with ModiQuest Research BV (“ModiQuest“) whereby the Company has agreed to acquire all of the issued and outstanding shares of ModiQuest (the “Transaction“). The Transaction continues to realize on the Board’s commitment … Continue reading

TetraGenetics and ModiQuest Collaborating for the Discovery of Therapeutic Antibodies against KCa3.1

Arlington, MA December 6, 2017 –– TetraGenetics, a biopharmaceutical company developing novel therapeutics for autoimmune diseases, today announced a collaboration with ModiQuest Research, a Dutch biotechnology company with a suite of technologies for the discovery and optimization of monoclonal antibodies, including those directed against difficult target antigens with low immunogenicity. The alliance is focused on … Continue reading

shopping basket 0 items

Shopping Cart

0

Your shopping cart is empty:

please visit the shop